Results 191 to 200 of about 322,744 (314)

[Neurology in Bohemian Lights]. [PDF]

Rev Neurol
Puy-Núñez A, Guitián-Pena A, Expósito-Ruiz I, Macías-Arribí M, Aldrey-Vázquez JM, Pías-Peleteiro JM.   +5 more
europepmc   +1 more source

Central nervous system infection by Bacillus cereus: a case report and literature review. [PDF]

Rev Neurol, 2022
Rollán-Martínez Herrera M, González-Urdiales P, Zubizarreta-Zamalloa A, Rodríguez-Merino E, Martínez-Dubarbie F.   +4 more
europepmc   +1 more source

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Identification of a variant in the USH1G gene in a family with Usher syndrome [PDF]

Biomedica
Gélvez N, López G, Tamayo ML.
europepmc   +1 more source

Prevalence and clinical characteristics of neurotrophic keratopathy in hispanic population in northeastern Mexico. [PDF]

Int Ophthalmol, 2023
Castillo-Macías A, Arreola-Martínez JE, Loya-García D, Valdez-García JE.   +3 more
europepmc   +1 more source

Cognitive Behavioral Therapy for Youth With Childhood‐Onset Lupus: A Randomized Clinical Trial

Arthritis Care &Research, EarlyView.
Objective Our objective was to determine the feasibility and acceptability of the Treatment and Education Approach for Childhood‐Onset Lupus (TEACH), a six‐session cognitive behavioral intervention addressing depressive, fatigue, and pain symptoms, delivered remotely to individual youth with lupus by a trained interventionist.
Natoshia R. Cunningham, Thea Senger‐Carpenter, Jocelyn Zuckerman, Michelle Adler, Mallet R. Reid, Ashley Danguecan, Luana Flores Pereira, Sarah I. Mossad, Samantha L. Ely, Khalid Abulaban, Elizabeth A. Kessler, Natalie Rosenwasser, Tamar B. Rubinstein, Ekemini A. Ogbu, Emily A. Smitherman, Alaina Miller, Taylor Abounader, Elizabeth Ross, Livie Timmerman, Dhriti Sharma, Jennifer N. Stinson, Stacy Allen, Kabita Nanda, Tala El Tal, Deborah M. Levy, Linda T. Hiraki, Hermine I. Brunner, Mathew Reeves, Steven J. Pierce, Andrea Knight   +29 more
wiley   +1 more source

[Murals, medicine, and memory: The cultural heritage of IMSS as a generator of institutional identity]. [PDF]

Rev Med Inst Mex Seguro Soc
Pacheco-Zavala MDP, Hernández-Ordóñez R, Smolinski-Kurek RL.   +2 more
europepmc   +1 more source

Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation–associated protein 5 (MDA5) antibody–associated dermatomyositis (DM). Methods Thirty patients with MDA5 antibody–associated DM were identified in a single‐center longitudinal cohort of 352
Jenice X. Cheah, Sangmee S. Bae, Tiffany De Leon, Yuna Lee, Rong Guo, David Elashoff, Jennifer Wang, Ani Shahbazian, Christina Charles‐Schoeman   +8 more
wiley   +1 more source

[Autism spectrum disorder: the impact of an online training strategy on the knowledge of the healthcare staff of a tertiary care hospital]. [PDF]

Rev Neurol
Alonzo-Castillo T, Lugo-Marín J, Robles M, Rossich R, Gallego L, González M, Setién-Ramos I, Martínez-Ramírez M, Ramos-Quiroga JA, Gisbert-Gustemps L.   +9 more
europepmc   +1 more source

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

Arthritis Care &Research, EarlyView.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie, Timothy Beukelman, Nicholas P. McCormick, Jeffrey R. Curtis   +3 more
wiley   +1 more source